MSD and Pfizer were 2018’s top gainers on the Dow Jones Industrial Average for the calendar year, with both companies bucking the trend of an otherwise lacklustre year for the index.
GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business and form a joint venture with combined annual sales
Pfizer is set to implement a new retail, hospital services and internet healthcare strategy in China as part of a deal with local online pharmacy and health services platform Jianke.
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting Pfizer’s patent dispute and allowing AbbVie